Physician profile
Mousa Matar
NPI 1992116982
$1,399.09
in general payments reported to CMS, 2019-2025
22 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $329 · 2023: $379 · 2024: $279 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $333.97 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $127.38 | 2023-2024 | Xarelto |
| Amgen INC. | $88.36 | 2022-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $78.60 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.30 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $77.38 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Xeris Pharmaceuticals, INC. | $67.23 | 2022-2025 | Gvoke Hypopen |
| Novo Nordisk INC | $67.14 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $62.00 | 2022 | |
| Exact Sciences Corporation | $51.86 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $49.12 | 2022-2023 | Eliquis |
| Glaxosmithkline, LLC. | $40.04 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.22 | 2023 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $36.65 | 2023 | Quviviq |
| Pfizer INC. | $29.57 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28.71 | 2022-2023 | Jardiance, Emgality |
| Astellas Pharma US INC | $27.43 | 2025 | Veozah |
| Viatris Specialty LLC | $25.56 | 2025 | Yupelri |
| Dexcom, INC. | $25.11 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $23.32 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.25 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mousa Matar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.